Mecasermin
drugOn this page
Also known as Bio-fd&c igf1CEP-151Cg-gf2Cg-igf-1Igf-1ecIncrelexInsulin-like growth factor 1Insulin-like growth factor iMecasermin recombinantMecaserminaMecasermineMechano growth factorMyotrophinNexpure plant-made igf-1Pv-802Pv802Rh-oligopeptide-2Sh-oligopeptide-2Somatomedin c
Summary
Mecasermin (CHEMBL1201716) is an approved protein (ATC H01AC03) targeting INSR and IGF1R; indicated across 17 conditions including hypothyroidism and laron syndrome.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- ATC class: H01AC03
- Targets: 2 (INSR, IGF1R)
- Indications: 17 conditions
- Clinical trials: 13
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201716 |
| Name | Mecasermin |
| Type | Protein |
| Max phase | 4 |
| ATC | H01AC03 |
Also known as: Bio-fd&c igf1, CEP-151, Cg-gf2, Cg-igf-1, Igf-1ec, Increlex, Insulin-like growth factor 1, Insulin-like growth factor i, Mecasermin, Mecasermin recombinant, Mecasermina, Mecasermine
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| INSR | Insulin receptor | Agonist | 0.8% | P06213 | |
| IGF1R | Insulin-like growth factor I receptor | Agonist | 19% | P08069 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 2 target gene(s): INSR, IGF1R.
Top Reactome pathways
16 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| PIP3 activates AKT signaling | 1 | INSR |
| Signal Transduction | 1 | INSR |
| Negative regulation of the PI3K/AKT network | 1 | INSR |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 1 | IGF1R |
| IRS-related events triggered by IGF1R | 1 | IGF1R |
| SHC-related events triggered by IGF1R | 1 | IGF1R |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 1 | INSR |
| IRS activation | 1 | INSR |
| Signal attenuation | 1 | INSR |
| Insulin receptor signalling cascade | 1 | INSR |
| Signaling by Insulin receptor | 1 | INSR |
| Insulin receptor recycling | 1 | INSR |
| Intracellular signaling by second messengers | 1 | INSR |
| Signaling by Receptor Tyrosine Kinases | 1 | INSR |
| Extra-nuclear estrogen signaling | 1 | IGF1R |
| Respiratory syncytial virus (RSV) attachment and entry | 1 | IGF1R |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| positive regulation of cell population proliferation | 2 |
| insulin receptor signaling pathway | 2 |
| positive regulation of cell migration | 2 |
| positive regulation of protein-containing complex disassembly | 2 |
| positive regulation of MAPK cascade | 2 |
| protein autophosphorylation | 2 |
| positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction | 2 |
| dendritic spine maintenance | 2 |
| amyloid-beta clearance | 2 |
| protein phosphorylation | 2 |
| cell surface receptor protein tyrosine kinase signaling pathway | 2 |
| positive regulation of receptor internalization | 1 |
| heart morphogenesis | 1 |
| regulation of DNA-templated transcription | 1 |
| receptor-mediated endocytosis | 1 |
Indications & clinical
Indications
17 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| hypothyroidism | 4 | MONDO:0005420 | EFO:0004705 |
| Laron syndrome | 4 | MONDO:0009877 | MONDO:0015892 |
| diabetes mellitus | 3 | MONDO:0005015 | EFO:0000400 |
| amyotrophic lateral sclerosis | 3 | MONDO:0004976 | MONDO:0004976 |
| Crohn disease | 2 | MONDO:0005011 | EFO:0000384 |
| bone disorder | 2 | MONDO:0005381 | EFO:0004260 |
| hyperinsulinism | 2 | MONDO:0002177 | MONDO:0002177 |
| retinopathy of prematurity | 2 | MONDO:0006952 | EFO:1001158 |
| multiple sclerosis | 2 | MONDO:0005301 | MONDO:0005301 |
| Rett syndrome | 2 | MONDO:0010726 | MONDO:0010726 |
| Noonan syndrome | 2 | MONDO:0018997 | MONDO:0018997 |
| anorexia nervosa | 1 | MONDO:0005351 | MONDO:0005351 |
| disease of the tendon | 0 | MONDO:0100010 | EFO:1001434 |
4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 13.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 5 |
| PHASE1/PHASE2 | 3 |
| EARLY_PHASE1 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00571727 | PHASE2/PHASE3 | COMPLETED | Long-Term Treatment With rhIGF-1 in GHIS |
| NCT00004700 | PHASE2 | COMPLETED | Phase II Long Term, Randomized Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism |
| NCT00490100 | PHASE1/PHASE2 | TERMINATED | Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1 |
| NCT01438086 | PHASE1/PHASE2 | COMPLETED | Evaluation of the Safety and Efficacy of Using Insulin-like Growth Factor-1 in Patients With a Heart Attack |
| NCT02636270 | PHASE1/PHASE2 | COMPLETED | IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency |
| NCT01329744 | PHASE1 | TERMINATED | Effects of IGF-I in HIV Metabolic Disease |
| NCT03932162 | EARLY_PHASE1 | RECRUITING | Gene Expression Changes In Young and Geriatric Skin |
| NCT01834989 | EARLY_PHASE1 | UNKNOWN | Patellar Tendinopathy - Effect of Training and Enhancement of the Collagen Synthesis by Insulin-like Growth Factor-I |
| NCT00004419 | Not specified | COMPLETED | Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin Resistance |
| NCT00004699 | Not specified | COMPLETED | Dose Ranging Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism |
| NCT01314508 | Not specified | WITHDRAWN | Increlex Treatment of Children With Chronic Liver Disease and Short Stature |
| NCT01446783 | Not specified | COMPLETED | IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients |
| NCT01588093 | Not specified | COMPLETED | IGF-I Induced Muscle Glucose Uptake and Interstitial IGF-I Concentrations |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
38 molecules share ≥1 primary target. Top 38 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| CRIZOTINIB | ChEMBL + PubChem | Phase 4 (approved) | IGF1R, INSR |
| Pazopanib | ChEMBL + PubChem | Phase 4 (approved) | IGF1R, INSR |
| BRIGATINIB | ChEMBL | Phase 4 (approved) | IGF1R, INSR |
| CERITINIB | ChEMBL | Phase 4 (approved) | IGF1R, INSR |
| ENTRECTINIB | ChEMBL | Phase 4 (approved) | IGF1R, INSR |
| FEDRATINIB | ChEMBL | Phase 4 (approved) | IGF1R, INSR |
| NINTEDANIB | ChEMBL | Phase 4 (approved) | IGF1R, INSR |
| SUNITINIB | ChEMBL | Phase 4 (approved) | IGF1R, INSR |
| LESTAURTINIB | ChEMBL | Phase 3 | IGF1R, INSR |
| LINSITINIB | ChEMBL | Phase 3 | IGF1R, INSR |
| BMS-754807 | ChEMBL | Phase 2 | IGF1R, INSR |
| CENISERTIB | ChEMBL | Phase 2 | IGF1R, INSR |
| ELLAGIC ACID | ChEMBL | Phase 2 | IGF1R, INSR |
| FORETINIB | ChEMBL | Phase 2 | IGF1R, INSR |
| ILORASERTIB | ChEMBL | Phase 2 | IGF1R, INSR |
| R-406 | ChEMBL | Phase 2 | IGF1R, INSR |
| TOZASERTIB | ChEMBL | Phase 2 | IGF1R, INSR |
| Afatinib | PubChem | Approved | IGF1R, INSR |
| belumosudil | PubChem | Approved | IGF1R, INSR |
| Binimetinib | PubChem | Approved | IGF1R, INSR |
| dacomitinib | PubChem | Approved | IGF1R, INSR |
| Fostamatinib | PubChem | Approved | IGF1R, INSR |
| Gefitinib | PubChem | Approved | IGF1R, INSR |
| Idelalisib | PubChem | Approved | IGF1R, INSR |
| regorafenib | PubChem | Approved | IGF1R, INSR |
| Selumetinib | PubChem | Approved | IGF1R, INSR |
| Trametinib | PubChem | Approved | IGF1R, INSR |
| INFIGRATINIB | ChEMBL | Phase 4 (approved) | INSR |
| LAPATINIB | ChEMBL | Phase 4 (approved) | INSR |
| NERATINIB | ChEMBL | Phase 4 (approved) | INSR |
| OSIMERTINIB | ChEMBL | Phase 4 (approved) | INSR |
| SORAFENIB | ChEMBL | Phase 4 (approved) | INSR |
| DOVITINIB | ChEMBL | Phase 3 | INSR |
| LINIFANIB | ChEMBL | Phase 3 | INSR |
| QUERCETIN | ChEMBL | Phase 3 | IGF1R |
| OSI-632 | ChEMBL | Phase 2 | INSR |
| SU-014813 | ChEMBL | Phase 2 | INSR |
| Belzutifan | PubChem | Approved | INSR |
Related Atlas pages
- Genes: INSR, IGF1R
- Diseases: hypothyroidism, Laron syndrome, diabetes mellitus, amyotrophic lateral sclerosis
- Drugs: Crizotinib, Pazopanib, Brigatinib, Ceritinib, Entrectinib, Fedratinib, Nintedanib, Sunitinib, Lestaurtinib, Linsitinib, Afatinib, belumosudil, Binimetinib, dacomitinib, Fostamatinib, Gefitinib, Idelalisib, regorafenib, Selumetinib, Trametinib, Infigratinib, Lapatinib, Neratinib, Osimertinib, Sorafenib, Dovitinib, Linifanib, Quercetin, Belzutifan